<http://schema.org/articleBody>
"A U.S. Food and Drug Administration committee recently recommended that the composition of the influenza vaccine for the 2013-2014 influenza season should be slightly altered from the current vaccine.<br /><br />The FDA's Vaccines and Related Biological Products Advisory Committee determined that the 2013-2014 vaccine should replace the A/Victoria/361/2011 (H3N2)-like virus with an A(H3N2) virus antigenically similar to the cell-propagated prototype virus A/Victoria/361/2011 (A/Texas/50/2012) during a meeting on February 27. The committee also recommended the replacement of current vaccine strain B/Wisconsin/1/2010-like virus with a B/Massachusetts/2/2012-like (B/Yamagata lineage) virus, <a title=\"http://www.medscape.com\" href=\"http://www.medscape.com\" target=\"_blank\">Medscape Medical News</a> reports.<br /><br />The committee recommended retaining the current vaccine strain A/California/7/2009pdm09-like (2009 H1N1) virus for the next season's trivalent vaccines.<br /><br />For quadrivalent vaccines, which are expected to be available for the upcoming season, the committee recommended the inclusion of the B/Brisbane/60/2008-like (B/Victoria lineage) virus in addition to the virus strains recommended for the trivalent vaccine.<br /><br />The committee based its recommendations on global influenza surveillance data and the availability of candidate strains and reagents.<br /><br />The recommendations of the committee matched the ones made by the World Health Organization for northern hemisphere influenza vaccines, <a title=\"http://www.medscape.com\" href=\"http://www.medscape.com\" target=\"_blank\">Medscape Medical News</a> reports.<br /><br />&nbsp;"^^<http://www.w3.org/2001/XMLSchema#string>
<http://vaccinenewsdaily.com/stories/510534156-fda-panel-recommends-strains-for-2013-2014-flu-vaccine>